GLP-1 is not just a drug story. It may quietly rewrite food demand

Most people are looking at GLP-1 as a pharma theme.

I think that is too narrow.

The more interesting part may be what these drugs do to food behaviour.

Because if a large number of consumers start eating less, feeling full faster, and becoming more careful about what they put into their body, then this is no longer just a healthcare story. It becomes a consumer behaviour story.

And that is where things get interesting.

For years, a large part of food demand was built around taste, habit, convenience, advertising and availability. But GLP-1 may start changing the basic question consumers ask before eating.

Earlier, the question was often:

What do I feel like eating?

Now, for many users, the question may slowly become:

If I am eating less, what should I eat that gives me more?

That one shift can have very wide implications.

During GLP-1 usage, food behaviour can change in a very practical way

A person on these drugs may not behave like a normal consumer anymore.

They may naturally:

- eat smaller portions

- avoid heavy, oily or very sugary foods

- snack less impulsively

- prefer simpler and easier-to-tolerate foods

- think more about protein, hydration and nutrient density

- shift from random eating to planned eating

And this is where the real consumer shift begins.

Because when appetite falls, stomach space reduces, and each meal becomes smaller, then every bite has to work harder.

Food is no longer just about filling up.

It starts becoming about:

- getting enough nutrition

- avoiding weakness

- feeling stable through the day

- maintaining muscle

- supporting energy levels even with lower intake

One under-discussed part: eating less does not mean the body needs less nutrition

This is where second-order thinking becomes important.

During GLP-1-led weight loss, some amount of muscle loss can also happen along with fat loss. On top of that, when food intake falls sharply, weakness, low energy, light-headedness or dizziness can become common complaints for some people.

That means one thing very clearly:

Even if people eat less, their need for good nutrition does not fall. In many cases, it may actually become more important.

And that creates a very different kind of demand.

The consumer may increasingly look for:

- protein-rich foods

- lower-sugar options

- nutrient-dense foods

- easy-to-consume solid foods

- liquid nutrition and hydration support

- products that help deliver more than just basic calories

So the basket may not simply become smaller.

It may become smarter, tighter and more functional.

The shift may be from “fun quantity” to “functional quality”

This does not mean indulgence disappears.

It simply means that for many users, the role of food may start changing.

A larger part of the basket may move toward:

- higher protein

- lower sugar

- portion-controlled eating

- hydration-led products

- easier digestion

- better ingredient quality

- foods and beverages that help support strength and recovery

In simple words, people may start asking less:

“What tastes good?”

And more:

“What helps me feel better, function better and still stay on track?”

That is a very different demand pattern.

The psychological change may be just as important as the physical one

GLP-1 may not only reduce appetite. It may also change a person’s relationship with food.

For some users, that may mean:

- less mindless eating

- less emotional snacking

- more control over cravings

- more conscious decision-making

- greater willingness to pay for “better calories”

That matters because once food becomes a more deliberate choice, the entire consumer decision tree changes.

Categories that depend heavily on impulse, overconsumption or sugar-heavy repeat behaviour may face pressure.

Categories linked to:

- control

- better nutrition

- lower sugar

- higher protein

- easier daily wellness habits

may start seeing a structural shift in attention.

The story does not end when the drug is stopped

This is the part I find even more interesting.

The market often thinks only about what happens during GLP-1 use.

But the real long-term impact may also come from what happens after.

Because after coming off these drugs, many people may try to preserve at least some of the habits they learned while using them.

And those habits can be powerful:

- smaller portions

- more protein

- less sugar

- more intentional eating

- lower tolerance for junk calories

- greater focus on foods that help maintain control

So post-GLP-1 consumer behaviour may split into two paths.

Path 1: old habits return, appetite rises, and the person slips back into earlier eating patterns.

Path 2: some habits stick, and the person actively looks for products that help maintain the new lifestyle even without the drug.

That second path is where a longer consumer trend may come from.

Because after using GLP-1, many people may not want to go back fully to old eating behaviour. They may still search for:

- lower-sugar substitutes

- portion-friendly options

- protein-led foods

- better snacking formats

- hydration support

- everyday products that make discipline easier

So the “after” phase may matter just as much as the “during” phase.

In other words, GLP-1 may create two waves of demand change

Wave 1: while using the drug

People eat less, feel fuller faster, and become more selective.

Wave 2: after the drug

People try to hold on to the better habits they built and look for products that support that effort.

This is why I think GLP-1 should not be looked at only as a temporary weight-loss trend.

It may end up creating a gradual rewiring of food behaviour itself.

One more subtle effect: fewer eating moments may raise quality expectations

If consumers start eating fewer times a day, then each eating moment becomes more important.

That can lead to:

- fewer but better choices

- less tolerance for empty calories

- greater importance of nutrient density

- stronger demand for foods that combine convenience with a “better for me” signal

- more room for solid and liquid nutrition formats that do more per serving

So even if the number of eating occasions falls, the value per eating occasion may rise.

That is a meaningful shift.

The real question is not just “will people eat less?”

That part is visible already.

The more important question is:

What happens when a large group of consumers starts treating food as part of weight management, strength, recovery, hydration and long-term self-control, rather than just hunger satisfaction?

Because once that happens, food stops being only about:

- taste

- price

- habit

It starts becoming about:

- control

- nourishment

- energy

- confidence

- quality

- getting more value out of fewer calories

My simple takeaway

GLP-1 may not just reduce food intake.

It may change the meaning of food itself.

During usage, it may push consumers toward:

smaller, cleaner, more functional eating

After usage, it may push many of them toward:

holding on to those better habits through smarter everyday choices

So the real theme may not simply be:

people eat less

It may actually be:

people eat less, but expect much more from what they eat

And if that happens at scale, the ripple effects across food, beverages, nutrition and wellness could be much bigger than the market currently assumes.

4 Likes

Alcohol companies are already feeling the pain. But a point of yours that habit is maintained has not been the case, most people(around 60-80% which is a large number) go back to their original body mass after stopping semaglutide injections within a year.

Fair point, and I broadly agree that one should not assume a straight-line behavioural change after stopping the drug.

My view is slightly more nuanced.

First, mass adoption impact is still ahead of us, so we are probably very early in judging what the full consumer effect will look like.

Second, I do think the user base itself may split into different buckets.

One bucket could be people with genuine obesity and related health issues, especially in the 40+ age group, where weight is often linked with diabetes, heart risk, joint issues, fatigue, etc. In such cases, once people see visible health benefits, they may become much stricter and more disciplined about what they eat. That is where new consumption trends can emerge. For example, higher protein, better nutrition, lower sugar, hydration, nutrient-dense foods and even liquid nutrition may move from being niche products for gym-goers to more mainstream everyday consumption.

The second bucket could be younger, short-term users — for example people using these drugs before weddings or for specific appearance-driven goals. In that segment, it is quite possible that once the immediate target is achieved, many may gradually drift back toward older eating habits and lifestyle patterns.

So I don’t think this is a binary outcome where either “everyone changes permanently” or “nobody changes at all.”

More likely, it will play out as a probability distribution.

Some users may revert fully.

Some may revert partly.

And some may permanently upgrade their food behaviour after experiencing the benefits of better eating and more controlled intake.

That is why, from an investing point of view, it may be better to think in terms of probabilities, cohorts and behavioural tendencies, rather than in terms of certainty.

The real question may not be whether all users maintain the habit.

The real question may be: if even a meaningful minority of users permanently shift toward higher protein, better nutrition and more intentional eating, can that itself create a large new market over time?

That, to me, is where the interesting possibility lies.

Glp-3 works even better. It’s not fda approved but as the procedure is known many pharma companies sell it on grey market

There are even websites that do a third party certification on quality

If you search reta on Reddit or Google there are several success stories on how people have transformed their bodies completely

Glp-1 patents have lapsed in India so there are not really affordable solutions. Someone online commented that the cost of food/restaurant meal saved due to smaller portions, pays for the cost of glp-1 !!!

Personally I feel like until oral drugs reach the efficacy of injectables, mass adoption/regular consumption of glp-1 similar to multivitamins is far off. Then we will see how it affects things like smoking, protein consumption and other temptations

1 Like

This is a pretty interesting take. I was trying to research on how consumer behaviour changes once the economy reached 3000-4000 usd per capita mark. India is in this phase itself. And the findings were a few behavioural shifts like :

  • More electronics and white goods penetration
  • Rise of preventive care vs post illness care
  • Huge change in food habits
  • Rise in experience economy (travel, leisure spends, entertainment etc.)

Change in food habits

  • Cereals lose their grip. The share of calories from rice, wheat, and millets falls as incomes rise — staples get replaced by meat, dairy, and oils. Already visible in India where cereal’s share of food budgets is falling across all income groups.

  • Animal protein rises, but the form is cultural. Developing countries saw meat consumption rise 150% and dairy 60% between 1964–99. China’s pork intake went from 37g/day (1992) to 64g/day (2012). India’s version will be dairy-led, not meat-led.

  • Eggs move first. Egg consumption has doubled globally, with sharper rises in developing countries. Cheapest, most culturally neutral animal protein — always the first to scale at this income level.

  • Processed food spending roughly doubles each decade. India’s per capita processed food sales went from $26 to $60 between 2010–2020. Richest urban Indian households already get ~30% of calories from processed food. China saw a 4x rise in processed food retail between 1999–2013.

  • Food-away-from-home surges with urbanization. Urban Chinese consumed 178g/day of animal foods vs 117g for rural — the gap driven by eating out. India is at the start of this curve.

  • Protein quantity improves slowly; quality barely moves. India’s per capita protein intake went from 60.7g to 61.8g/day (rural) and 60.3g to 63.4g/day (urban) between 2011–2024 — barely a rounding error over 13 years. Nearly half still comes from cereals, a poor-quality source.

  • Food share of income falls; absolute spend rises. Food is 40% of household spend in low-income economies, 22% in middle-income — but the rupee amount spent climbs, shifting toward higher-value categories.

    India footnote: Animal protein is just 9–10% of daily calories here vs global norms. The $3k transition in India will accelerate dairy, eggs, processed food, and eating out — not a Western-style meat consumption. GLP-1 likely suppresses the processed snack and sugary beverage categories acting as another micro tailwind for Indian food habit shifts.

Very interesting framework. I broadly agree that once per capita income rises, the way people consume starts changing, not just the amount they consume.

Food is a great example. As incomes rise, people usually move from basic calorie satisfaction to better taste, convenience, protein, dairy, processed foods, eating out, and eventually more premium choices. We are already seeing parts of that shift in India.

But the bigger question is: what actually pushes people toward healthy eating?

Because if we go by current data i.e. latest economic survey, India is also seeing a rise in ultra-processed food consumption. So higher income alone does not automatically mean healthier eating. In many cases, it can just mean more discretionary consumption, not necessarily better consumption.

That is where I think a catalyst may matter.

GLP-1 drugs, especially if lower-cost generics start becoming widely available over time, could become one such catalyst. Not immediately, and not with certainty, but as a probability this is worth thinking about. Obesity is becoming one of the biggest health issues in the country, and it brings along many other serious problems. If that is the backdrop, then a product that directly pushes appetite control, portion reduction, and more conscious eating can potentially alter food behaviour in a way that rising incomes alone may not.

In that sense, GLP-1 may not just be a pharma story. It may become a consumer behaviour trigger.

And if that happens, it could expand multiple addressable markets.

Take protein as an example. Today, a large part of protein-focused consumption is still associated with gym-goers, athletes, and fitness enthusiasts. But if GLP-1 adoption rises meaningfully among people dealing with obesity, then protein intake may no longer remain a niche fitness trend. It could increasingly become part of a broader health-management routine for a much larger set of consumers.

That would mean the market shifts from:

fitness-led protein consumption

to

health-led protein consumption

And that is a much bigger market.

Same logic can extend to:

- nutrient-dense foods

- easy-to-consume liquid nutrition

- portion-friendly foods

So yes, the per capita income transition already creates a favourable backdrop for food habit change. But GLP-1 could act as an additional accelerant by pushing consumers from simply eating more premium to eating more intentionally.

Again, I would still look at all this on a probability basis, not as certainty.

The key question is not whether everyone changes.

The key question is: if even a meaningful minority changes eating behaviour in a durable way, can that itself create a much larger market than what exists today?

That possibility, to me, is worth tracking closely.

I totally agree that having catalysts will push the habit changes and GLP-1 sort of aligns very well there. How much is or will GLP-1 is aiding to the food habits change that I am not sure how to track. One way to do is correlation between GLP-1 adoption and protein consumption per capita? And there is one differentiation that you pointed out that is processed food consumption that should go down with GLP-1 adoption but the per income capita actually encourages processed food consumption given people start to have less time to cook their own food with more work.

Anyways when the behaviour shift happens meaningfully in food habits, be it due to GLP-1 or not it is still a big thing and a structural change. I think behavioural shifts are hard to reverse, take financialization of savings as an example. Even in the current markets downturn we are seeing record AUM growth for mutual funds. This is a proof that habits don’t reverse or die out easily.

Are you keeping an eye out for a particular secotor or businesses benefitting from this probably upcoming trend?

Currently, I am closely watching both the pharmaceutical and consumption sectors to see if and when a clear trend emerges.